• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Chemicon International, Inc. Releases Innovative Infectious Disease Detection Product

Posted on: Thursday, 22 September 2005, 12:00 CDT

Serologicals Corporation (NASDAQ: SERO) announced today that Chemicon International, Inc., its wholly-owned subsidiary based in Temecula, CA, has launched a new proprietary Amplifluor(R) ID Pan-Enterovirus Detection Reagent. This product rapidly detects Pan-Enterovirus. This is the first of many infectious disease detection products to be offered utilizing Chemicon's patented fluorescent detection technology, Amplifluor(R).

Enteroviruses cause a wide variety of disease ranging from polio, meningitis-encephalitis, myocarditis, hand-foot-and-mouth disease, conjunctivitis, and numerous other syndromes associated with intestinal organs. Chemicon's Amplifluor(R) ID Pan-Enterovirus Detection Reagent provides a sensitive, specific and rapid real-time method detection of enteroviruses.

The patented real-time Amplifluor(R) fluorescent detection system is a powerful and flexible platform that can be utilized for a variety of nucleic acid amplification techniques. Amplifluor(R) can be incorporated into a wide array of analytical applications appropriate to HTS in drug discovery with other applications in genomics, clinical diagnostics, forensics, biothreat and food testing. In addition, Amplifluor(R) has been successfully used with strand displacement amplification, nucleic acid sequence-based amplification, and cascade rolling-circle amplification techniques.

Chemicon currently has several other viral detection targets in development leveraging the Amplifluor(R) technology platform: Hepatitis B, Parvovirus B19, Babesia, Erhlichia, Lyme Disease, Influenza A & B, Herpes Simplex Viruses 1 & 2, and West Nile. This patented platform technology allows for rapid real-time testing.

Chemicon International, Inc. offers a broad range of research products, including specialty reagents, kits, antibodies, and custom products and services, to customers working in the areas of neuroscience, stem cell biology, cancer, and infectious disease research. It is also a leading supplier of monoclonal antibodies, conjugates, antibody blends and molecular-based detection kits for use in diagnostic laboratories. Chemicon focuses on basic and biomedical research, drug discovery, and diagnostics, allowing it to serve thousands of customers worldwide in the academic, clinical, biotechnology, and pharmaceutical sectors. Acquired in 2003, Chemicon is a Serologicals company, based in Temecula, CA.

For more information, please visit our website: www.chemicon.com.

Serologicals Corporation (NASDAQ: SERO), headquartered in Atlanta, GA., is a global leader in developing and commercializing consumable biological products, enabling technologies and services in support of biological research, drug discovery, and the bioprocessing of life-enhancing products. Our customers include researchers at major life science companies and leading research institutions involved in key disciplines, such as neurology, oncology, hematology, immunology, cardiology, proteomics, infectious diseases, cell signaling and stem cell research. In addition, Serologicals is the world's leading provider of monoclonal antibodies for the blood typing industry. Serologicals employs a total of more than 1,000 people worldwide in three Serologicals' companies: Chemicon International, headquartered in Temecula, CA, Upstate Group, LLC, headquartered in Charlottesville, VA. and Celliance Corporation, headquartered in Atlanta, GA.

For more information, please visit our website: www.serologicals.com.

This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words or phrases such as "should result,""are expected to,""we anticipate,""we estimate,""we project" or similar expressions are intended to identify forward-looking statements. These statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those expressed in any forward-looking statements. These risks and uncertainties include, without limitation, the value of the licensed research tools and the utility of the licensed research tools to researchers. You should not place undue reliance on forward-looking statements, since the statements speak only as of the date that they are made, and the Company undertakes no obligation to update these statements based on events that may occur after the date of this press release.

Serologicals is a registered trademark of Serologicals Investment Company.

Amplifluor(R) is a registered trademark of Chemicon International, Inc.

Amplifluor(R) technology is covered under US patents 5,866,336, 6,090,552, and 6,117,635 and related foreign patents.

Source: Business Wire

More News in this Category